The stock of INSTITUTE OF BIOMEDICAL RESEARCH CORP N (OTCMKTS:MRES) registered a decrease of 83.67% in short interest. MRES’s total short interest was 20,000 shares in March as published by FINRA. Its down 83.67% from 122,500 shares, reported previously. With 16,500 shares average volume, it will take short sellers 1 days to cover their MRES’s short positions.

It closed at $0.0011 lastly. It is down 0.00% since March 17, 2018 and is . It has underperformed by 4.37% the S&P500.

Neuro-Biotech Corp. provides biomedical research and analytical services in Montenegro and internationally. The company has market cap of $. The Company’s services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental medical treatments. It currently has negative earnings. The firm also researchers and develops new biomedical and food products; provides programs for graduate research studies in biomedical and environmental fields; offers two channel analog NMS, digital muscle stimulator, digital TENS, interferential, elite combination, portable four channel digital, portable ultra sound, and other healthcare devices; and provides photon red light for beauty, electric pain relief products, microcurrent electrical nerve stimulators, and high volt pulsed stimulators.

More recent Institute of Biomedical Research Corp. (OTCMKTS:MRES) news were published by: which released: “The 10 Best Stocks for Your 401k –” on November 28, 2017. Also published the news titled: “Martinrea International: At 5x EPS, 3.5x EBITDA, And 1.1x TBV, Improving Fundamentals Make It Too Cheap To Ignore – Seeking Alpha” on August 22, 2018.‘s news article titled: “Zero Hedge Has Zero Chance of Submitting Facebook Stock –” with publication date: March 14, 2019 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.